Cannabis Microdoses Show Promise in Halting Alzheimer's Cognitive Decline

Breakthrough Brazilian Study Challenges Traditional Treatment

A groundbreaking clinical trial from Brazil has produced unexpected results in the fight against Alzheimer's disease. This represents the first clinical trial to successfully test the microdose approach in patients with Alzheimer's disease , offering new hope where conventional treatments have fallen short.

The study, led by Professor Francisney Nascimento and colleagues at the Federal University of Latin American Integration (UNILA), recruited 24 elderly patients (60-80 years) diagnosed with mild Alzheimer's . It evaluated the effects of daily use of an oil prepared from cannabis extract containing THC and CBD in similar proportions and extremely low concentrations (0.3 mg of each cannabinoid) .

The research began after the group initially tested microdosing of cannabis extract in a single patient with Alzheimer's disease for 22 months , which showed promising cognitive improvements and sparked the larger controlled trial.

Remarkable Results Without Side Effects

After 24 weeks of treatment, the group receiving the cannabis extract showed stabilisation in their scores, while the placebo group showed cognitive deterioration (worsening of Alzheimer's symptoms) . The impact was modest but relevant, patients using cannabis microdosing scored two to three points higher than their placebo counterparts on the widely-used Mini-Mental State Examination.

Perhaps most remarkably, the results found positive effects, without the associated "high" of cannabis . No psychoactive effects or significant adverse events were observed . Alzheimer's patients typically decline between 3 to 4 MMSE points per year. The stabilization and slight improvement observed in the cannabis group contrast with the expected decline and are comparable to, or even superior to, the modest effects of standard therapies such as acetylcholinesterase inhibitors .

Scientific Mechanisms Behind the Success

The therapeutic approach targets the brain's endocannabinoid system, which naturally declines with age. The endocannabinoid system, which is important for neuroprotection and regulates normal brain activity (ranging from body temperature to memory), undergoes a natural decline during ageing .

Microdoses of cannabis can escape the psychoactive zone and still deliver benefits . The approach using microdoses of cannabinoids represents a multi-target strategy, potentially capable of modulating diverse pathogenic mechanisms of the disease, such as neuroinflammation and oxidative stress .

Looking Toward Clinical Applications

While the study shows promise, researchers acknowledge limitations. The sample size is small, and the effects were restricted to one dimension of the cognition scale . New studies with a larger number of participants, longer follow-up times, and in combination with biological markers (such as neuroimaging and inflammatory biomarkers) will be necessary .

This could open the door to new formulations focused on prevention, especially in more vulnerable populations, such as elderly people with mild cognitive impairment or a family history of dementia . With the world's population aging and the number of people living with dementias such as Alzheimer's disease increasing , this research represents a potential paradigm shift in how we approach neurodegenerative diseases.

The findings suggest that extremely low doses of cannabis compounds might offer a safe, effective intervention that could slow or halt cognitive decline without the complications associated with traditional cannabis use. This breakthrough opens new avenues for research and could eventually transform treatment options for millions facing this devastating disease.